Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.78 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | MMP1 | P03956 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.99 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.99 |
| ▸ | LMNA | P02545 | 1/20 | 0.99 |
| ▸ | HPGD | P15428 | 1/20 | 0.99 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.99 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL19534323 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL12313065 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL29367581 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL131381 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4034 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL13420262 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL1501478 | 0.99 | GLA (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4164613 | 0.99 | GLA (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL663859 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL5693425 | 0.99 | PAX8 (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 578 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729561-A1 | POLYETHYLENE GLYCOL DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4602052-A1 | PROTEIN-BASED SIGNAL AMPLIFICATION | California Institute of Technology (US) | 2025-08-20 | — | — | EP | claimed |
| WO-2024235132-A9 | COMPOUND HAVING BIOLOGICAL ACTIVITY, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | claimed |
| WO-2024235134-A9 | CONJUGATE HAVING TARGETING EFFECT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | claimed |
| WO-2024235136-A9 | HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | claimed |
| EP-4565240-A1 | COMBINATION THERAPY FOR TREATING CANCERS | Geistlich Pharma AG (CH) | 2025-06-11 | — | — | EP | claimed |
| WO-2025026226-A1 | POLYETHYLENE GLYCOL SMALL MOLECULE DRUG, PREPARATION METHOD THEREFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2025-02-06 | — | — | WO | claimed |
| WO-2024255854-A1 | POLYETHYLENE GLYCOL DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2024-12-19 | — | — | WO | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| WO-2022212005-A2 | ACOUSTIC REMOTE CONTROL OF MICROBIAL IMMUNOTHERAPY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-10-06 | — | — | WO | claimed |
| CN-115103689-A | Dendrimer compositions and methods for drug delivery | 阿什瓦塔治疗股份有限公司 | 2022-09-23 | — | — | CN | claimed |
| WO-2022125590-A1 | A SYNTHETIC CIRCUIT FOR CELLULAR MULTISTABILITY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-16 | — | — | WO | claimed |
| US-20220175706-A1 | CALCIUM LACTATE COMPOSITIONS AND METHODS OF USE | METIMEDI PHARMACEUTICALS CO., LTD. (KR) | 2022-06-09 | — | — | US | claimed |
| WO-2022111616-A1 | ANTI-CLDN18.2 ANTIBODY, DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 石药集团巨石生物制药有限公司 | 2022-06-02 | — | — | WO | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| WO-2022068898-A1 | PREPARATION METHOD FOR BIS-SUBSTITUTED BRIDGING ANTIBODY-DRUG CONJUGATE | 迈威(上海)生物科技股份有限公司 | 2022-04-07 | — | — | WO | claimed |
| US-11285121-B2 | Calcium lactate compositions and methods of use | METIMEDI PHARMACEUTICALS CO., LTD. (KR) | 2022-03-29 | — | — | US | claimed |
| EP-3968962-A1 | METHODS OF MAKING NANOCRYSTALS WITH ENHANCED BIOLOGICAL AVAILABILITY AND FORMULATION FOR SUCH NANOCRYSTALS PREPARATION FOR USE IN ANTICANCER THERAPY | Tomas Bata University In Zlín (CZ) | 2022-03-23 | — | — | EP | claimed |
| WO-2022052823-A1 | SMALL-MOLECULE CONJUGATE AND USE THEREOF | 上海邈基生物科技有限公司 | 2022-03-17 | — | — | WO | claimed |